Smithbridge Asset Management Inc. DE Has $10.14 Million Stock Holdings in Novo Nordisk A/S $NVO

Smithbridge Asset Management Inc. DE lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 110.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 199,188 shares of the company’s stock after buying an additional 104,709 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Novo Nordisk A/S were worth $10,135,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NVO. Jessup Wealth Management Inc acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $124,000. Signet Private Wealth LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter worth about $227,000. Janney Montgomery Scott LLC raised its stake in Novo Nordisk A/S by 107.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 332,003 shares of the company’s stock worth $16,892,000 after purchasing an additional 172,075 shares in the last quarter. GFS Advisors LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at about $286,000. Finally, Deutsche Bank AG grew its position in shares of Novo Nordisk A/S by 290.7% during the 4th quarter. Deutsche Bank AG now owns 501,839 shares of the company’s stock worth $25,534,000 after purchasing an additional 373,381 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported that its Wegovy pill has surpassed 3 million prescriptions, signaling strong early demand for the oral obesity treatment and reinforcing the company’s competitive position versus Eli Lilly in the fast-growing GLP-1 market. Novo Wegovy Pill Tops 3M Prescriptions
• Positive Sentiment: The company also said that more than 80% of Wegovy pill customers have never used a GLP-1 before, which suggests the product is expanding Novo’s addressable market beyond existing obesity-drug users. Novo Nordisk CEO interview on Wegovy pill customers
• Positive Sentiment: Novo Nordisk introduced an updated Rybelsus tablet formulation in Canada, adding a more convenient version of its diabetes GLP-1 drug and supporting the company’s broader cardiometabolic franchise. Novo Nordisk introduces updated Rybelsus tablet formulation in Canada
• Neutral Sentiment: Several articles highlighted Novo Nordisk as a key beneficiary of the GLP-1 boom and as part of healthcare ETF exposure themes, which may keep the stock in focus but do not change fundamentals directly. Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
• Neutral Sentiment: Novo’s CEO reiterated that the company aims to be a “cardiometabolic powerhouse” with a diversified pipeline, reinforcing a long-term growth narrative. Novo Nordisk CEO interview
• Negative Sentiment: Novo Nordisk is also heading to court in South Africa to try to stop sales of unapproved semaglutide copies, underscoring ongoing legal and counterfeit-product risks tied to its blockbuster drugs. Novo Nordisk faces off in court with South African weight-loss drug compounder

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research report on Tuesday, March 3rd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $42.73 on Thursday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $190.78 billion, a price-to-earnings ratio of 10.03, a P/E/G ratio of 3.78 and a beta of 0.78. The firm’s 50 day simple moving average is $41.98 and its 200 day simple moving average is $46.04. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion during the quarter. As a group, research analysts expect that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.